Keita Endo

Keita Endo

Auto-generated profile, based on publicly available information

Keita Endo

Department of Nephrology, Endocrinology and Diabetes, Tokyo Bay Urayasu Ichikawa Medical Center , Urayasu, 3-4-32 Todaijima Urayasu-city, Chiba 2790001

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Acute Medicine & Surgery
Verified
Journal Article
Open access
PDF file
KTKei Takehara
Kei Takehara
MMMichiko Mizobe
Michiko Mizobe
KEKeita Endo
Keita Endo
AMAkihiro Miyake
Akihiro Miyake
TSToshihiko Suzuki
Toshihiko Suzuki
HFHiraku Funakoshi
Hiraku Funakoshi
Background: We report a case of acute renal failure with loin pain and patchy renal ischemia after anaerobic exercise (ALPE) caused by sudden training resumption.Case presentation: A 19‐year‐old Asian man who was a college American football player presented with severe back pain, headache, and malaise. He developed acute kidney injury without myoglobinuria. Based on the typical medical history and symptoms, we made a diagnosis of ALPE. Symptoms improved within a few days, and serum creatinine levels improved after discharge. He resumed training, adjusting his load step by step.Conclusion: During the coronavirus disease 2019 pandemic, many athletes were unable to undergo adequate training. Long‐term de‐training leads to decreased various organ function and reduces the anaerobic threshold. Rapid resumption after prolonged de‐training may put individuals at risk of developing ALPE.

19 August 2025 in Journal of the Endocrine Society
Verified
Journal Article
Open access
KTKeisuke Takano
Keisuke Takano
KHKoichi Hayashi
Koichi Hayashi
KKKoichi Kitamura
Koichi Kitamura
MKMutsuo Kanda
Mutsuo Kanda
KIKei Ito
Kei Ito
TSToshihiko Suzuki
Toshihiko Suzuki
Context: The fibrosis-4 (FIB-4) index is a noninvasive marker for liver fibrosis and is associated with the occurrence of diabetic kidney disease (DKD). Although sodium-glucose cotransporter-2 inhibitors (SGLT2is) are recognized to provide cardiovascular and renal benefits, the role of SGLT2is in regulating FIB-4 index and the subsequent effect on renal events remain unclear. Objective: This work aimed to clarify whether the FIB-4 index was associated with the development of DKD (estimated glomerular filtration rate < 60 mL/min/1.73 m2 or new-onset macroalbuminuria) and whether the background treatment with other antidiabetic drugs modified the effects of SGLT2i on FIB-4 index and renal events. Methods: A retrospective cohort study was conducted that included 136 patients with type 2 diabetes mellitus who were newly given SGLT2is for 3 years. Results: Patients with a high FIB-4 index (≥1.3) at baseline exhibited a higher incidence of de novo DKD, compared to those with a lower FIB-4 index (<1.3). This association was ameliorated in patients whose FIB-4 index was decreased during the SGLT2i treatment. Finally, among the background therapies, metformin use was associated with a decrease in FIB-4 index and a lower cumulative incidence of de novo DKD. Conclusion: Elevated FIB-4 index at baseline is a potent predictor for developing DKD, and combination therapy with SGLT2is and metformin may enhance renal protection by modulating FIB-4 index.